The dysfunction of VHL leads to hypoxia-inducible factor (HIF) hyperactivation, resulting in overexpression of many downstream genes involved in angiogenesis, metabolism, and cell-cycle regulation, which represent critical therapeutic targets for patients with ccRCC [3, 4] (Fig. 1). This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.